New Thrombopoietic Growth Factors

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Feb 10

PMID 17289815

Citations 77

Authors

David J Kuter

Affiliations

Soon will be listed here.

Abstract

Although development of first-generation thrombopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF]) was stopped due to development of antibodies to PEG-rHuMGDF, nonimmunogenic second-generation thrombopoietic growth factors with unique pharmacologic properties have been developed. TPO peptide mimetics contain TPO receptor-activating peptides inserted into complementarity-determining regions of Fab (Fab 59), attached to the IgG Fc region (AMG 531), or pegylated (Peg-TPOmp). Orally available, TPO nonpeptide mimetics (eltrombopag, AKR-501) bind and activate the TPO receptor by a mechanism different from TPO and may have an additive effect to TPO. TPO agonist antibodies are monoclonal antibodies activating the TPO receptor but modified in size [TPO minibodies; ie, VB22B sc(Fv)(2)] or immunoglobuln type (domain subclass-converted TPO agonist antibodies; ie, MA01G4G344). All second-generation thrombopoietic growth factors stimulate growth of TPO-dependent cell lines via JAK2/STAT signaling pathways and increase platelet counts in animals. When tested in healthy humans, TPO peptide and nonpeptide mimetics produced a dose-dependent rise in platelet count. AMG 531 and eltrombopag markedly increase platelet counts in patients with immune thrombocytopenic purpura, without significant adverse effects. One or more second-generation thrombopoietic growth factors should soon be clinically available for treating thrombocytopenic disorders.

Citing Articles

Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort study.

Feng D, Liu Q, Gao H, Cao Y, Chen X, Zhang R Br J Haematol. 2024; 206(2):769-772.

PMID: 39676311 PMC: 11829132. DOI: 10.1111/bjh.19954.

Immune Thrombocytopenic Purpura (ITP) With Ulcerative Colitis (UC).

Mohammed S, Budamagunta S, Khan W, Khan M, Lippmann S Cureus. 2024; 16(10):e72778.

PMID: 39618596 PMC: 11608085. DOI: 10.7759/cureus.72778.

Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.

Stability, challenges, and prospects of chitosan for the delivery of anticancer drugs and tissue regenerative growth factors.

Rahman M, Mondal M Heliyon. 2024; 10(21):e39879.

PMID: 39583848 PMC: 11582409. DOI: 10.1016/j.heliyon.2024.e39879.

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.

Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z Signal Transduct Target Ther. 2024; 9(1):166.

PMID: 38945949 PMC: 11214942. DOI: 10.1038/s41392-024-01852-x.

References

Safonov I, Heerding D, Keenan R, Price A, Erickson-Miller C, Hopson C . New benzimidazoles as thrombopoietin receptor agonists. Bioorg Med Chem Lett. 2005; 16(5):1212-6. DOI: 10.1016/j.bmcl.2005.11.096. View

Kuter D, Goodnough L, Romo J, DiPersio J, Peterson R, Tomita D . Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001; 98(5):1339-45. DOI: 10.1182/blood.v98.5.1339. View

de Sauvage F, Hass P, Spencer S, Malloy B, Gurney A, Spencer S . Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994; 369(6481):533-8. DOI: 10.1038/369533a0. View

Stoffel R, Wiestner A, Skoda R . Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996; 87(2):567-73. View

de Serres M, Ellis B, Dillberger J, Rudolph S, Hutchins J, Boytos C . Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells. 1999; 17(4):203-9. DOI: 10.1002/stem.170203. View

Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W . Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997; 336(6):404-9. DOI: 10.1056/NEJM199702063360603. View

Harker L, Hunt P, Marzec U, Kelly A, Tomer A, Hanson S . Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996; 87(5):1833-44. View

Archimbaud E, Ottmann O, Yin J, Lechner K, Dombret H, Sanz M . A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999; 94(11):3694-701. View

Alexander W, Metcalf D, Dunn A . Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995; 14(22):5569-78. PMC: 394671. DOI: 10.1002/j.1460-2075.1995.tb00244.x. View

10.

Gurney A, Wong S, Henzel W, de Sauvage F . Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A. 1995; 92(12):5292-6. PMC: 41680. DOI: 10.1073/pnas.92.12.5292. View

11.

Kuter D, Rosenberg R . Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood. 1994; 84(5):1464-72. View

12.

Ulich T, Del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S . Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996; 87(12):5006-15. View

13.

Vadhan-Raj S, Kavanagh J, Freedman R, Folloder J, Currie L, Bueso-Ramos C . Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002; 359(9324):2145-52. DOI: 10.1016/S0140-6736(02)09090-6. View

14.

Livnah O, Stura E, Middleton S, Johnson D, Jolliffe L, Wilson I . Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999; 283(5404):987-90. DOI: 10.1126/science.283.5404.987. View

15.

Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F . AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009; 82(4):247-54. DOI: 10.1111/j.1600-0609.2008.01198.x. View

16.

Harker L . Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol. 1998; 35(3):241-52. View

17.

Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R . Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-8. DOI: 10.7326/0003-4819-132-5-200003070-00005. View

18.

Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View

19.

Lok S, Kaushansky K, Holly R, Kuijper J, Oort P, Grant F . Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994; 369(6481):565-8. DOI: 10.1038/369565a0. View

20.

Duffy K, Shaw A, Delorme E, Dillon S, Erickson-Miller C, Giampa L . Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002; 45(17):3573-5. DOI: 10.1021/jm025535c. View